Serum proprotein convertase subtilisin/kexin type 9 levels correlate with depression severity in post-stroke patients

Table 3 Changes in depression and anxiety scores over 12 weeks

Outcome measure	Treatment group	Control group	P value
HAMD-17 score at baseline	22.8 ± 4.5	22.3 ± 4.2	0.516
HAMD-17 score at 4 weeks	18.3 ± 3.8	19.6 ± 3.9	0.076
HAMD-17 score at 8 weeks	13.7 ± 3.5	16.8 ± 3.7	< 0.001
HAMD-17 score at 12 weeks	10.2 ± 3.1	14.6 ± 3.8	< 0.001
HAMA score at 12 weeks	8.5 ± 2.3	12.1 ± 3.2	< 0.001
Treatment response rate (%)	73.4 (45/61)	48.4 (30/62)	0.003
Remission rate (HAMD-17 < 7, %)	52.5 (32/61)	29.0 (18/62)	0.007

HAMD-17: 17-item Hamilton Depression Rating Scale; HAMA: Hamilton Anxiety Scale.